← Back to Search

Immunosuppressant

1 for Liver Disease (thymo Trial)

Phase 4
Waitlist Available
Led By Wendy Grant, MD
Research Sponsored by University of Nebraska
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post op days 1-6, months 3,6, 9, and 12
Awards & highlights

thymo Trial Summary

The purpose of this study is to compare kidney function, long term patient and graft survival, and incidence of acute rejection in liver transplant recipients between one group receiving thymoglobulin induction and delayed initiation of tacrolimus and another group of liver transplant recipients having immediate administration of tacrolimus without any induction immunosuppression.

Eligible Conditions
  • Liver Disease
  • Liver Transplant
  • Immunosuppression

thymo Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post op days 1-6, months 3,6, 9, and 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and post op days 1-6, months 3,6, 9, and 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evaluation of renal function via Glo-Fil nuclear medicine scan and laboratory parameters
Secondary outcome measures
patient and graft survival, incidence of acute rejection, incidence of active CMV disease, incidence of other infections, any adverse events or serious adverse events associated with the use of thymo induction therapy

thymo Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: 1Experimental Treatment1 Intervention
Patients in arm 1 will receive induction with thymoglobulin at time of transplant with delayed initiation of tacrolimus
Group II: 2Active Control1 Intervention
patients in arm 2 will not receive thymo induction at time of transplant and will have immediate initiation of tacrolimus

Find a Location

Who is running the clinical trial?

University of NebraskaLead Sponsor
537 Previous Clinical Trials
1,143,854 Total Patients Enrolled
Genzyme, a Sanofi CompanyIndustry Sponsor
524 Previous Clinical Trials
85,530 Total Patients Enrolled
Wendy Grant, MDPrincipal InvestigatorUniversity of Nebraska

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of Thymoglobulin and Tacrolimus in Liver Transplant
2007. "A Study of Thymoglobulin and Tacrolimus in Liver Transplant". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00564538.
All > Liver Transplant
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top